Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE - PubMed
6 hours ago
- #HIV
- #cardiometabolic risk
- #integrase inhibitors
- Study examines cardiometabolic risks after switching to integrase strand-transfer inhibitors (INSTIs) in people with HIV at low-to-moderate cardiovascular risk using REPRIEVE trial data.
- Findings show higher risks of obesity (HR 1.41), diabetes (HR 1.50), and hypertension (HR 1.45) in INSTI switchers compared to non-switchers over 5 years.
- No significant effect on major adverse cardiovascular events (MACE) was observed (HR 1.17).
- Most switchers initiated dolutegravir-based regimens, while non-switchers commonly used efavirenz-based regimens.
- Highlights the need for long-term monitoring of cardiometabolic comorbidities in individuals switching to INSTIs to manage future risks.
- Study funded by NIH, Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare, with various authors reporting industry conflicts.